{
    "title": "110_s3187",
    "content": "The Act may be cited as the \"Lung Cancer Mortality Reduction Act of 2008\". Congress finds that lung cancer is the leading cause of cancer death, surpassing other types of cancer combined. Despite advancements in research for other cancers, the 5-year survival rate for lung cancer remains low at 15 percent, highlighting the need for a focused research effort to improve survivability rates. (5) Sixty percent of lung cancer cases are diagnosed in nonsmokers or former smokers, with two-thirds of nonsmokers being women. Certain minority populations, like African-American males, have high rates of lung cancer despite similar smoking rates. Baby boomers entering their sixties are at higher risk. Tobacco addiction, exposure to carcinogens like Agent Orange, and battlefield emissions are concerns for military personnel. Improved access to treatment can lead to significant reductions in lung cancer mortality. Lung cancer screening tests can reduce mortality in at-risk individuals. Additional strategies are needed to improve diagnosis and treatment. Funding for lung cancer research is insufficient compared to its health impact. Integrated research consortia focused on lung cancer are a top priority. The United States aims to reduce lung cancer mortality by 50% by 2015 through a coordinated effort and targeted funding. The Senate emphasizes the need for a national public health priority to reduce lung cancer mortality and calls for a comprehensive program coordinated by the Secretary of Health and Human Services. Additionally, a new Lung Cancer Mortality Reduction Program is proposed under the Public Health Service Act. The Lung Cancer Mortality Reduction Act of 2008 mandates a program to reduce lung cancer mortality by 50% by 2015, involving various government agencies and stakeholders. The Lung Cancer Mortality Reduction Act of 2008 requires the National Institutes of Health to prioritize research grants to reduce lung cancer mortality, expand research programs on lung cancer predispositions and related diseases, and enhance imaging and bioengineering programs. The Lung Cancer Mortality Reduction Act of 2008 aims to expedite the development of innovative diagnostic, surgical, and drug testing technologies to reduce lung cancer mortality. It includes provisions for expanding research programs, establishing a drug program, and enabling compassionate access activities through the Food and Drug Administration. The Lung Cancer Mortality Reduction Act of 2008 includes provisions for establishing a lung cancer mortality reduction program, conducting biannual reviews of screening protocols, and coordinating minority and health disparity programs to address the burden of lung cancer on minority populations. The Lung Cancer Mortality Reduction Act of 2008 aims to reduce lung cancer mortality by coordinating drug cessation treatments with early detection protocols. Appropriations are authorized for activities in subsections (b)(1)(B), (b)(1)(C), and (b)(1)(D) for fiscal years 2009 through 2013. The Lung Cancer Mortality Reduction Act of 2008 authorizes appropriations for fiscal years 2009 through 2013 for specific activities related to drug cessation treatments and early detection protocols under the Food, Drug, and Cosmetic Act. The Lung Cancer Mortality Reduction Program is authorized under the Lung Cancer Mortality Reduction Act of 2008 for activities related to drug cessation treatments and early detection protocols. The Secretary will implement a program to provide incentives for the development of chemoprevention drugs, targeted therapeutic treatments, and vaccines for lung cancer, as well as agents to prevent nicotine addiction. The program will follow the provisions of subchapter B for drugs, biological products, and devices related to the prevention and treatment of lung cancer. The Lung Cancer Mortality Reduction Act of 2008 establishes a Board to monitor the development of lung cancer treatments. Access to unapproved therapies includes compassionate use of drugs, biological products, and devices. The CDC is involved in the program under Title XV of the Public Health Service Act. The CDC is involved in the Lung Cancer Mortality Reduction Act of 2008 under Title XV of the Public Health Service Act. The Lung Cancer Mortality Reduction Program aims to address high mortality rates among minority and low-income populations through early disease research and management. Authorization of appropriations is provided for the program. The Secretary of Defense and the Secretary of Veterans Affairs will coordinate with the Secretary of Health and Human Services in developing a Lung Cancer Mortality Reduction Program, implementing an early detection and disease management research program for military personnel and veterans at risk for lung cancer, and implementing coordinated care programs for those diagnosed with lung cancer. Additionally, a Lung Cancer Advisory Board will be established. The Secretary of Health and Human Services will establish a Lung Cancer Advisory Board to monitor programs under the Act, provide reports to Congress, and include representatives from various fields. Authorization of appropriations is also included. Authorization of appropriations is included for the programs under this Act for fiscal years 2009 through 2013."
}